Description
As the GLP1 therapy landscape shifts in 2026, clinical success is being redefined by more than just numbers on a scale. Join Dr. Sean Wharton for an essential update on the diversification of the GLP-1 market, including the impact of new therapeutic entries on patient access. This session moves beyond weight-centric management to explore the systemic, multi-organ benefits of GLP-1s, providing a blueprint for achieving total metabolic health and long-term quality of life in your patients.